Salud renal para todos en todas partes. Desde la prevención hasta la detección y al acceso equitativo a la atención
Palabras clave:
enfermedad renal; prevención; detección; conciencia; acceso a la salud; equidad; cobertura universal de salud; Día Mundial del Riñón
Citas
1) International Society of Nephrology. United Nations Hight Level Meeting on Universal Health Coverage. Moving together to build Kidney Health Worldwide [Internet]. ISN, 2019. Disponible en: https://www.theisn.org/images/Advocacy_4_pager_2019_Final_WEB_pagebypage.pdf (Consulta: 20/07/2019).
2) Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018;392(10159):2052-90.
3) Essue BM, Laba T, Knaul F, Chu A, Van Minh H, Phuong Nguyen TH, et al. Economic burden of chronic ill health and injuries for households in low- and middle-income countries. In: Jamison DT, Gelband H, Horton S, Jha P, Laxminarayan R, Mock CN, et al., eds. Disease control priorities: improving health and reducing poverty 3rd ed. Washington, DC: World Bank, 2018, p. 121-43.
4) Luyckx VA, Tuttle KR, Garcia-Garcia G, Gharbi MB, Heerspink HJL, Johnson DW, et al. Reducing major risk factors for chronic kidney disease. Kidney Int Suppl. 2017;7(2):71-87.
5) Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018; 96(6):414-22D.
6) Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380(9844): 807-14.
7) Kalantar-Zadeh K, Fouque D. Nutritional management of chronic kidney disease. N Engl J Med. 2017;377(18):1765-76.
8) United Nations General Assembly. Political declaration of the third high-level meeting of the General Assembly on the prevention and control of non-communicable diseases [Internet]. Oct. 2018. Disponible en: https://www.un.org/ga/search/view_doc.asp?symbol=A/73/L.2&Lang=E (Consulta: 20/07/2019).
9) López AD, Williams TN, Levin A, Tonelli M, Singh JA, Burney PG, et al. Remembering the forgotten non-communicable diseases. BMC Med. 2014;12:200.
10) Estados Unidos. Centers for Disease Control and Prevention. Picture of America [Internet]. Washington DC: CDC, 2019. Disponible en: https://www.cdc.gov/pictureofamerica/index.html (Consulta: 20/07/2019).
11) Levey AS, Schoolwerth AC, Burrows NR, Williams DE, Stith KR, McClellan W. Comprehensive public health strategies for preventing the development, progression, and complications of CKD: report of an expert panel convened by the Centers for Disease Control and Prevention. Am J Kidney Dis. 2009;53(3):522-35.
12) Saran R, Robinson B, Abbott KC, Agodoa LYC, Bragg-Gresham J, Balkrishnan R, et al. US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2019;73(3S1):A7-A8.
13) Kovesdy CP, Furth SL, Zoccali C; World Kidney Day Steering Committee. Obesity and kidney disease: hidden consequences of the epidemic. J Ren Nutr. 2017;27(2):75-7.
14) Tantisattamo E, Dafoe DC, Reddy UG, Ichii H, Rhee CM, Streja E, et al. Current management of acquired solitary kidney. Kidney Int Rep. 2019;4(9):1205-18.
15) Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238-52.
16) Koppe L, Fouque D. The role for protein restriction in addition to renin-angiotensin-aldosterone system inhibitors in the management of CKD. Am J Kidney Dis. 2019;73(2):248-57.
17) Rifkin DE, Coca SG, Kalantar-Zadeh K. Does AKI truly lead to CKD? J Am Soc Nephrol. 2012;23(6):979-84.
18) Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407-18.
19) Verhave JC, Troyanov S, Mongeau F, Fradette L, Bouchard J, Awadalla P, et al. Prevalence, awareness, and management of CKD and cardiovascular risk factors in publicly funded health care. Clin J Am Soc Nephrol. 2014;9(4):713-9.
20) Chow KM, Szeto CC, Kwan B, Leung CB, Li PK. Public lacks knowledge on chronic kidney disease: telephone survey. Hong Kong Med J. 2014;20(2):139-44.
21) Ene-Iordache B, Perico N, Bikbov B, Carminati S, Remuzzi A, Perna A, et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Glob Health. 2016;4(5):e307-19.
22) Li PK, Weening JJ, Dirks J, Lui SL, Szeto CC, Tang S, et al. A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease, Hong Kong, June 29, 2004. Kidney Int Suppl. 2005;(94):S2-7.
23) Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis. 2007;50(2):169-80.
24) Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007;72(3):247-59.
25) Crowe E, Halpin D, Stevens P; Guideline Development Group. Early identification and management of chronic kidney disease: summary of NICE guidance. BMJ. 2008;337:a1530.
26) Li PK, Chow KM, Matsuo S, Yang CW, Jha V, Becker G, et al. Asian chronic kidney disease best practice recommendations: positional statements for early detection of chronic kidney disease from Asian Forum for Chronic Kidney Disease Initiatives (AFCKDI). Nephrology (Carlton). 2011;16(7):633-41.
27) Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald R, Rossini D, et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2012;156(8):570-81.
28) Li PK, Ng JK, Cheng YL, Kwan TH, Leung CB, Lau MF, et al. Relatives in silent kidney disease screening (RISKS) study: A Chinese cohort study. Nephrology (Carlton). 2017;22(Suppl. 4):35-42.
29) Samal L, Linder JA. The primary care perspective on routine urine dipstick screening to identify patients with albuminuria. Clin J Am Soc Nephrol. 2013;8(1):131-5.
30) George C, Mogueo A, Okpechi I, Echouffo-Tcheugui JB, Kengne AP. Chronic kidney disease in low-income to middle-income countries: the case for increased screening. BMJ Glob Health. 2017;2(2):e000256.
31) Gonzalez-Quiroz M, Nitsch D, Hamilton S, O'Callaghan Gordo C, Saran R, Glaser J, et al. Rationale and population-based prospective cohort protocol for the disadvantaged populations at risk of decline in eGFR (CO-DEGREE). BMJ Open. 2019;9(9):e031169.
32) Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA. 2003;290(23):3101-14.
33) Go DS, Kim SH, Park J, Ryu DR, Lee HJ, Jo MW. Cost-utility analysis of the National Health Screening Program for chronic kidney disease in Korea. Nephrology (Carlton). 2019;24(1):56-64.
34) Komenda P, Ferguson TW, Macdonald K, Rigatto C, Koolage C, Sood MM, et al. Cost-effectiveness of primary screening for CKD: a systematic review. Am J Kidney Dis. 2014;63(5):789-97.
35) Hwang SJ, Tsai JC, Chen HC. Epidemiology, impact and preventive care of chronic kidney disease in Taiwan. Nephrology (Carlton). 2010;15(Suppl. 2):3-9.
36) Almaguer M, Herrera R, Alfonso J, Magrans C, Mañalich R, Martínez A. Primary health care strategies for the prevention of end-stage renal disease in Cuba. Kidney Int. 2005;68( 97):S4-10.
37) Alamaguer-López M, Herrera-Valdez R, Díaz J, Rodríguez O. Integration of chronic kidney disease prevention into noncommunicable disease programs in Cuba. En: G. García-García, LY Agodoa, KC Norris (eds.). Chronic kidney disease in disadvantaged population. London: Elsevier, 2017, pp. 357-65.
38) Estados Unidos. Department of Health and Human Services. Advancing american kidney health [Internet]. Disponible en: https://aspe.hhs.gov/system/files/pdf/262046/AdvancingAmericanKidneyHealth.pdf (Consulta: 20/07/2019).
39) Estados Unidos. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation. The Special Diabetes Program for Indians. Estimates of Medicare savings [Internet]. ASPE Issue Brief, may 10 2019. Disponible en: https://aspe.hhs.gov/system/files/pdf/261741/SDPI_Paper_Final.pdf (Consulta: 26/09/2019).
40) Bello AK, Nwankwo E, El Nahas AM. Prevention of chronic kidney disease: a global challenge. Kidney Int Suppl. 2005;(98):S11-7.
41) James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet. 2010; 375(9722):1296-309.
42) Cortés-Sanabria L, Cabrera-Pivaral CE, Cueto-Manzano AM, Rojas-Campos E, Barragán G, Hernández-Anaya M, et al. Improving care of patients with diabetes and CKD: a pilot study for a cluster-randomized trial. Am J Kidney Dis. 2008;51(5):777-88.
43) Martínez-Ramírez HR, Jalomo-Martínez B, Cortés-Sanabria L, Rojas-Campos E, Barragán G, Alfaro G, et al. Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist. Am J Kidney Dis. 2006;47(1):78-87.
44) Cueto-Manzano AM, Martínez-Ramírez HR, Cortes-Sanabria L, Rojas-Campos E. CKD screening and prevention strategies in disadvantaged populations. The role of primary health care professionals. En: G. Garcia-Garcia, LY Agodoa, KC Norris (eds.). Chronic kidney disease in disadvantaged population. London: Elsevier, 2017, pp. 329-35.
45) Tapia-Conyer R, Gallardo-Rincon H, Betancourt-Cravioto M. Chronic kidney disease in disadvantaged populations: Online educational programs for NCD prevention and treatment. En: G. Garcia-Garcia, LY Agodoa, KC Norris (eds.). Chronic kidney disease in disadvantaged population. London: Elsevier, 2017, pp. 337-45.
46) Bello AK, Levin A, Manns BJ, Feehally J, Drueke T, Faruque L, et al. Kidney Health for Life Initiative. Effective CKD care in european countries: challenges and opportunities for health policy. Am J Kidney Dis. 2015;65(1):15-25.
47) Sharif MU, Elsayed M E, Stack AG. The global nephrology workforce: emerging threats and potential solutions. Clin Kidney J. 2016;9(1):11-22.
48) Naicker S, Eastwood JB, Plange-Rhule J, Tutt RC. Shortage of healthcare workers in sub-Saharan Africa: a nephrological perspective. Clin Nephrol. 2010;74(Suppl 1):S129-33.
49) Cusumano AM, Rosa-Diez GJ, González-Bedat MC. Latin American Dialysis and Transplant Registry: Experience and contributions to end-stage renal disease epidemiology. World J Nephrol. 2016;5(5):389-97.
50) Feehally J, Brusselmans A, Finkelstein FO, Harden P, Harris D, Manuzi G, et al. Improving global health: measuring the success of capacity building outreach programs: a view from the International Society of Nephrology. Kidney Int Suppl. 2016; 6(2): 42-51.
51) Harris DC, Dupuis S, Couser WG, Feehally J. Training nephrologists from developing countries: does it have a positive impact? Kidney Int Suppl. 2012;2(3):275-8.
52) Morbidity and mortality of renal dialysis: an NIH consensus conference statement. Consensus Development Conference Panel. Ann Intern Med. 1994;121(1): 62-70.
53) García-García G, Martínez-Castellanos Y, Renoirte-Lopez K, Barajas-Murguia A, de la Torre-Campos L, Becerra-Muñóz LE, et al. Multidisciplinary care for poor patients with chronic kidney disease in Mexico. Kidney Int Suppl. 2013;3(2):178-83.
54) Stanifer JW, Von Isenburg M, Chertow GM, Anand S. Chronic kidney disease care models in low- and middle-income countries: a systematic review. BMJ Glob Health. 2018;3(2):e000728.
55) Narva AS, Norton JM, Boulware LE. Educating patients about CKD: the path to self-management and patient-centered care. Clin J Am Soc Nephrol. 2016;11(4):694-703.
56) Schatell D. Web-based kidney education: supporting patient self-management. Semin Dial. 2013;26(2):154-8.
2) Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018;392(10159):2052-90.
3) Essue BM, Laba T, Knaul F, Chu A, Van Minh H, Phuong Nguyen TH, et al. Economic burden of chronic ill health and injuries for households in low- and middle-income countries. In: Jamison DT, Gelband H, Horton S, Jha P, Laxminarayan R, Mock CN, et al., eds. Disease control priorities: improving health and reducing poverty 3rd ed. Washington, DC: World Bank, 2018, p. 121-43.
4) Luyckx VA, Tuttle KR, Garcia-Garcia G, Gharbi MB, Heerspink HJL, Johnson DW, et al. Reducing major risk factors for chronic kidney disease. Kidney Int Suppl. 2017;7(2):71-87.
5) Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018; 96(6):414-22D.
6) Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380(9844): 807-14.
7) Kalantar-Zadeh K, Fouque D. Nutritional management of chronic kidney disease. N Engl J Med. 2017;377(18):1765-76.
8) United Nations General Assembly. Political declaration of the third high-level meeting of the General Assembly on the prevention and control of non-communicable diseases [Internet]. Oct. 2018. Disponible en: https://www.un.org/ga/search/view_doc.asp?symbol=A/73/L.2&Lang=E (Consulta: 20/07/2019).
9) López AD, Williams TN, Levin A, Tonelli M, Singh JA, Burney PG, et al. Remembering the forgotten non-communicable diseases. BMC Med. 2014;12:200.
10) Estados Unidos. Centers for Disease Control and Prevention. Picture of America [Internet]. Washington DC: CDC, 2019. Disponible en: https://www.cdc.gov/pictureofamerica/index.html (Consulta: 20/07/2019).
11) Levey AS, Schoolwerth AC, Burrows NR, Williams DE, Stith KR, McClellan W. Comprehensive public health strategies for preventing the development, progression, and complications of CKD: report of an expert panel convened by the Centers for Disease Control and Prevention. Am J Kidney Dis. 2009;53(3):522-35.
12) Saran R, Robinson B, Abbott KC, Agodoa LYC, Bragg-Gresham J, Balkrishnan R, et al. US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2019;73(3S1):A7-A8.
13) Kovesdy CP, Furth SL, Zoccali C; World Kidney Day Steering Committee. Obesity and kidney disease: hidden consequences of the epidemic. J Ren Nutr. 2017;27(2):75-7.
14) Tantisattamo E, Dafoe DC, Reddy UG, Ichii H, Rhee CM, Streja E, et al. Current management of acquired solitary kidney. Kidney Int Rep. 2019;4(9):1205-18.
15) Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238-52.
16) Koppe L, Fouque D. The role for protein restriction in addition to renin-angiotensin-aldosterone system inhibitors in the management of CKD. Am J Kidney Dis. 2019;73(2):248-57.
17) Rifkin DE, Coca SG, Kalantar-Zadeh K. Does AKI truly lead to CKD? J Am Soc Nephrol. 2012;23(6):979-84.
18) Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407-18.
19) Verhave JC, Troyanov S, Mongeau F, Fradette L, Bouchard J, Awadalla P, et al. Prevalence, awareness, and management of CKD and cardiovascular risk factors in publicly funded health care. Clin J Am Soc Nephrol. 2014;9(4):713-9.
20) Chow KM, Szeto CC, Kwan B, Leung CB, Li PK. Public lacks knowledge on chronic kidney disease: telephone survey. Hong Kong Med J. 2014;20(2):139-44.
21) Ene-Iordache B, Perico N, Bikbov B, Carminati S, Remuzzi A, Perna A, et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Glob Health. 2016;4(5):e307-19.
22) Li PK, Weening JJ, Dirks J, Lui SL, Szeto CC, Tang S, et al. A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease, Hong Kong, June 29, 2004. Kidney Int Suppl. 2005;(94):S2-7.
23) Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis. 2007;50(2):169-80.
24) Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007;72(3):247-59.
25) Crowe E, Halpin D, Stevens P; Guideline Development Group. Early identification and management of chronic kidney disease: summary of NICE guidance. BMJ. 2008;337:a1530.
26) Li PK, Chow KM, Matsuo S, Yang CW, Jha V, Becker G, et al. Asian chronic kidney disease best practice recommendations: positional statements for early detection of chronic kidney disease from Asian Forum for Chronic Kidney Disease Initiatives (AFCKDI). Nephrology (Carlton). 2011;16(7):633-41.
27) Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald R, Rossini D, et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2012;156(8):570-81.
28) Li PK, Ng JK, Cheng YL, Kwan TH, Leung CB, Lau MF, et al. Relatives in silent kidney disease screening (RISKS) study: A Chinese cohort study. Nephrology (Carlton). 2017;22(Suppl. 4):35-42.
29) Samal L, Linder JA. The primary care perspective on routine urine dipstick screening to identify patients with albuminuria. Clin J Am Soc Nephrol. 2013;8(1):131-5.
30) George C, Mogueo A, Okpechi I, Echouffo-Tcheugui JB, Kengne AP. Chronic kidney disease in low-income to middle-income countries: the case for increased screening. BMJ Glob Health. 2017;2(2):e000256.
31) Gonzalez-Quiroz M, Nitsch D, Hamilton S, O'Callaghan Gordo C, Saran R, Glaser J, et al. Rationale and population-based prospective cohort protocol for the disadvantaged populations at risk of decline in eGFR (CO-DEGREE). BMJ Open. 2019;9(9):e031169.
32) Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA. 2003;290(23):3101-14.
33) Go DS, Kim SH, Park J, Ryu DR, Lee HJ, Jo MW. Cost-utility analysis of the National Health Screening Program for chronic kidney disease in Korea. Nephrology (Carlton). 2019;24(1):56-64.
34) Komenda P, Ferguson TW, Macdonald K, Rigatto C, Koolage C, Sood MM, et al. Cost-effectiveness of primary screening for CKD: a systematic review. Am J Kidney Dis. 2014;63(5):789-97.
35) Hwang SJ, Tsai JC, Chen HC. Epidemiology, impact and preventive care of chronic kidney disease in Taiwan. Nephrology (Carlton). 2010;15(Suppl. 2):3-9.
36) Almaguer M, Herrera R, Alfonso J, Magrans C, Mañalich R, Martínez A. Primary health care strategies for the prevention of end-stage renal disease in Cuba. Kidney Int. 2005;68( 97):S4-10.
37) Alamaguer-López M, Herrera-Valdez R, Díaz J, Rodríguez O. Integration of chronic kidney disease prevention into noncommunicable disease programs in Cuba. En: G. García-García, LY Agodoa, KC Norris (eds.). Chronic kidney disease in disadvantaged population. London: Elsevier, 2017, pp. 357-65.
38) Estados Unidos. Department of Health and Human Services. Advancing american kidney health [Internet]. Disponible en: https://aspe.hhs.gov/system/files/pdf/262046/AdvancingAmericanKidneyHealth.pdf (Consulta: 20/07/2019).
39) Estados Unidos. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation. The Special Diabetes Program for Indians. Estimates of Medicare savings [Internet]. ASPE Issue Brief, may 10 2019. Disponible en: https://aspe.hhs.gov/system/files/pdf/261741/SDPI_Paper_Final.pdf (Consulta: 26/09/2019).
40) Bello AK, Nwankwo E, El Nahas AM. Prevention of chronic kidney disease: a global challenge. Kidney Int Suppl. 2005;(98):S11-7.
41) James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet. 2010; 375(9722):1296-309.
42) Cortés-Sanabria L, Cabrera-Pivaral CE, Cueto-Manzano AM, Rojas-Campos E, Barragán G, Hernández-Anaya M, et al. Improving care of patients with diabetes and CKD: a pilot study for a cluster-randomized trial. Am J Kidney Dis. 2008;51(5):777-88.
43) Martínez-Ramírez HR, Jalomo-Martínez B, Cortés-Sanabria L, Rojas-Campos E, Barragán G, Alfaro G, et al. Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist. Am J Kidney Dis. 2006;47(1):78-87.
44) Cueto-Manzano AM, Martínez-Ramírez HR, Cortes-Sanabria L, Rojas-Campos E. CKD screening and prevention strategies in disadvantaged populations. The role of primary health care professionals. En: G. Garcia-Garcia, LY Agodoa, KC Norris (eds.). Chronic kidney disease in disadvantaged population. London: Elsevier, 2017, pp. 329-35.
45) Tapia-Conyer R, Gallardo-Rincon H, Betancourt-Cravioto M. Chronic kidney disease in disadvantaged populations: Online educational programs for NCD prevention and treatment. En: G. Garcia-Garcia, LY Agodoa, KC Norris (eds.). Chronic kidney disease in disadvantaged population. London: Elsevier, 2017, pp. 337-45.
46) Bello AK, Levin A, Manns BJ, Feehally J, Drueke T, Faruque L, et al. Kidney Health for Life Initiative. Effective CKD care in european countries: challenges and opportunities for health policy. Am J Kidney Dis. 2015;65(1):15-25.
47) Sharif MU, Elsayed M E, Stack AG. The global nephrology workforce: emerging threats and potential solutions. Clin Kidney J. 2016;9(1):11-22.
48) Naicker S, Eastwood JB, Plange-Rhule J, Tutt RC. Shortage of healthcare workers in sub-Saharan Africa: a nephrological perspective. Clin Nephrol. 2010;74(Suppl 1):S129-33.
49) Cusumano AM, Rosa-Diez GJ, González-Bedat MC. Latin American Dialysis and Transplant Registry: Experience and contributions to end-stage renal disease epidemiology. World J Nephrol. 2016;5(5):389-97.
50) Feehally J, Brusselmans A, Finkelstein FO, Harden P, Harris D, Manuzi G, et al. Improving global health: measuring the success of capacity building outreach programs: a view from the International Society of Nephrology. Kidney Int Suppl. 2016; 6(2): 42-51.
51) Harris DC, Dupuis S, Couser WG, Feehally J. Training nephrologists from developing countries: does it have a positive impact? Kidney Int Suppl. 2012;2(3):275-8.
52) Morbidity and mortality of renal dialysis: an NIH consensus conference statement. Consensus Development Conference Panel. Ann Intern Med. 1994;121(1): 62-70.
53) García-García G, Martínez-Castellanos Y, Renoirte-Lopez K, Barajas-Murguia A, de la Torre-Campos L, Becerra-Muñóz LE, et al. Multidisciplinary care for poor patients with chronic kidney disease in Mexico. Kidney Int Suppl. 2013;3(2):178-83.
54) Stanifer JW, Von Isenburg M, Chertow GM, Anand S. Chronic kidney disease care models in low- and middle-income countries: a systematic review. BMJ Glob Health. 2018;3(2):e000728.
55) Narva AS, Norton JM, Boulware LE. Educating patients about CKD: the path to self-management and patient-centered care. Clin J Am Soc Nephrol. 2016;11(4):694-703.
56) Schatell D. Web-based kidney education: supporting patient self-management. Semin Dial. 2013;26(2):154-8.
Publicado
2020-03-17
Cómo citar
1.
Li PK-T, García-García G, Siu-Fai L, Andreoli S, Fung WW-S, Hradsky A, Kumaraswami L, Liakopoulo V, Rakhimova Z, Saadi G, Strani L, Ulasi I, Kalantar-Zadeh K. Salud renal para todos en todas partes. Desde la prevención hasta la detección y al acceso equitativo a la atención. Rev Nefrol Dial Traspl. [Internet]. 17 de marzo de 2020 [citado 21 de diciembre de 2024];40(1):1-13. Disponible en: http://revistarenal.org.ar/index.php/rndt/article/view/502
Sección
Editorial
Derechos de autor 2020 Revista de Nefrología, Diálisis y Trasplante
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0.
